Which superinvestors hold Edwards Lifesciences Corp (EW)?

Per the latest SEC 13F filings, 3 superinvestors hold Edwards Lifesciences Corp (EW): Ray Dalio, David Rolfe, Jeremy Grantham. Combined value held is about $41.7M, with Ray Dalio the largest holder.

← Stocks

Edwards Lifesciences Corp

EWAbove value

Held by 3 superinvestors.

Price$90.78

Holders3

Total value$41.7M

SEC 10-K · fundamentals

Business quality

as of 2025-12-31

Valuation basis: trailing twelve months to 2026-06-30 — latest 10-K plus unaudited 10-Q filings.

Revenue growth: +11.5%
Net margin: 17.7%
ROE: 10.4%
FCF margin: 22.0%

Revenue $4.39B → $6.07B · 6y

What makes a business high quality

Valuation · value band

Above fair value

$16/ sh · growth-anchored intrinsic value

margin of safety

fair value

above fair value

$91

cheaperpricier

Zero-growth floor

$17

Central IV

$16

Optimistic top

$27

Edwards Lifesciences Corp (EW): Two methods value the business — a conservative owner-earnings DCF and a growth-credited Greenwald estimate, $17–$27 / sh. Today’s price sits above both (price $91 as of 2026-08-26).

The middle figure is the main read. The right end is the optimistic case under the same conservative caps — not an absolute ceiling.

Recent earnings are below the multi-year average, so the band uses the lower run-rate.

Revenue growth 0% (history declining, capped at zero) · moat 10 yr · discount 10.6% · Zero-growth downside $17

Price as of 2026-08-26 · yahoo · DGS10 4.7% @ 2026-08-26.

Method & numbers

Model cautions

The two methods’ midpoints differ materially — growth assumptions warrant review (over 20%).

A conservative intrinsic-value band (zero-growth floor to growth-capped DCF) plus a tangible asset floor — not investment advice, not a buy/sell signal, and not a price target.

Owner-earnings DCF $14.11 – $18.49 · Greenwald $27.30 – $27.30 (neutral $27.30) · zero-growth base $27.30 · reproduction $16.66

Moat Franchise (moat) · terminal value 37% of present value · owner-earnings yield 2% vs 10Y 4.7%.

Graham earnings-power value (normalized NOPAT)$23.06 – $27.30 / sh

Normalized NOPAT = average operating margin over the years shown × latest-year revenue × (1 − normalized tax); then + D&A − maintenance capex (write A). Unlevered (pre-interest, attributable to all capital). Capitalized at the 9–11% rate band (read as a WACC proxy). Enterprise → equity bridge applied: + cash − total debt.

Years: TTM 2026-06-30, 2024, 2023, 2022, 2021

v1 simplifications: Maintenance capex (ok) deducted in full cash (write A): EPV = (NOPAT + D&A − maintenance capex) / WACC; no tax shield on the capex term. Share-based compensation is left as a real expense (not added back). Operating margin is below its multi-year average (cyclical/declining): normalized margin capped at the latest year — no peak-margin capitalization (audit #2).

Buffett owner-earnings value$15.39 – $18.81 / sh

Owner earnings = average net income + average D&A − maintenance capex (zero-growth floor; no ΔNWC). Levered (starts from net income, already after interest — an equity-holder stream). Capitalized at the 9–11% rate band (read as a cost-of-equity proxy). No enterprise→equity bridge: the capitalized result is already equity value (subtracting debt would double-count interest).

Years: TTM 2026-06-30, 2024, 2023, 2022, 2021

v1 simplifications: Net income is below its multi-year average (cyclical/declining): normalized owner earnings anchored to the latest year — no peak-earnings capitalization (audit #2). Owner earnings = net income + D&A − maintenance capex (ok); the working-capital change is excluded (maintenance ΔNWC ≈ 0; growth ΔNWC is carried in growth value, not double-counted). One-time items are not separately normalized (multi-year averaging smooths them partially). Share-based compensation is left as a real expense (not added back); see the SBC/OE disclosure. Capitalized at the 9–11% band as a cost-of-equity proxy; no leverage premium applied (net cash or debt within the no-charge range).

Reproduction value = tangible net assets $7.28B + capitalized R&D $2.34B（FY 2026, 2024, 2023, 2022） = $16.66 / sh. Reproduction value = tangible net assets (equity − goodwill − intangibles) + capitalized R&D (5y straight-line), ÷ diluted shares.

Moat reading: Franchise test compares earnings power (EPV) against reproduction value on both AV_conservative (tangible + capitalized R&D) and AV_reproduction (conservative + acquired-reset proxy). Both must clear the franchise multiple for a moat signal; near it, a commodity; below it, value destruction. A directional reading, not a verdict.

Assumes a narrow moat · competitive-advantage period ≈ 10 years.

Growth value: if the moat holds for 10 yr at ROIIC ≈ -19%, $0.00–$0.00 / sh (neutral $0.00). Conservative, not a forecast.

Window TTM 2026-06-30, FY 2024, 2023, 2022, 2021 · discount band 9%–11% · normalized tax 16% (Average effective tax rate over 5 year(s), capped at the statutory 21%.) · diluted shares.

Owner-earnings DCF: growth g₁ 0% (history declining → capped at 0) · OE FY TTM 2026-06-30, 2024, 2023, 2022, 2021 · Discount band: 9.16%–12.00% (DGS10 +4.5% to a 12% strict end, as of 2026-08-26). No enterprise→equity bridge: owner earnings already flow to shareholders (post-interest), so no net cash is added and no debt subtracted — matching the engine owner-earnings lamp. Two-method midpoint gap 52%.

Valuation basis: trailing twelve months to 2026-06-30 — latest 10-K plus unaudited 10-Q filings.

What the price is betting

Today's price pencils in about over 30.0% (outside the usual range) a year in owner-earnings for the next few years. Revenue actually grew 5.4% a year.

The market wants it well ahead of its own track record.

Even when the value band is low-confidence: use this to see what the price assumes — not as a cheapness confirmation.

How to read intrinsic value

SEC 13F · holders

Superinvestors Holding This Security

3 holders · $41.7M combined · this quarter +0 opened / -1 exited

This quarter2 added1 trimmed1 exited

Holders 4 → 3 · last 8q

Investor	Value	Shares	Weight (prev→now)
Ray Dalio	$24.9M	275,279	0.1% → 0.1% ▲
David Rolfe	$14.9M	165,208	2.8% → 3.1% ▲
Jeremy Grantham	$1.9M	20,664	0.0% → 0.0% ▲

Ray Dalio
Value$24.9MWeight (prev→now)0.1% → 0.1% ▲
David Rolfe
Value$14.9MWeight (prev→now)2.8% → 3.1% ▲
Jeremy Grantham
Value$1.9MWeight (prev→now)0.0% → 0.0% ▲

Exited this quarter (1)

Andreas Halvorsen

SEC 13F · notes

Written summary

Edwards Lifesciences Corp (EW) is held by 3 of the superinvestors tracked on Compounder, with a combined $41.7M in reported 13F value. The largest position belongs to Ray Dalio, where it makes up 0.1% of the portfolio.

Other notable holders by value include David Rolfe (3.1% of its book) and Jeremy Grantham (0.0% of its book).

Over the latest quarter, 0 of the tracked filers opened a new position in EW, 2 added to existing ones, 1 trimmed, and 1 sold out entirely.

Holder counts and values reflect the most recent SEC Form 13F filings, through the quarter ended 2026-06-30. Source: SEC EDGAR. A 13F shows only long US-listed positions and can lag the real portfolio by up to 45 days, so this is disclosed long ownership, not a complete picture.

How to read a 13F

SEC 13F · co-ownership

Also held by these investors

Investors holding Edwards Lifesciences Corp (EW) also commonly hold →

See which stocks look cheap against a conservative value band. Browse all valued stocks

Also on

Sources· SEC EDGAR 13F as of 2026-06-30 · filed 2026-08-14

Educational data only — not investment advice. 13F positions are self-reported and can lag up to 45 days.

Stay Updated

New-quarter 13F moves and valuation updates, to your inbox.